DE69732483D1 - Heterocyclische azahexan-derivate mit antiviraler wirkung - Google Patents

Heterocyclische azahexan-derivate mit antiviraler wirkung

Info

Publication number
DE69732483D1
DE69732483D1 DE69732483T DE69732483T DE69732483D1 DE 69732483 D1 DE69732483 D1 DE 69732483D1 DE 69732483 T DE69732483 T DE 69732483T DE 69732483 T DE69732483 T DE 69732483T DE 69732483 D1 DE69732483 D1 DE 69732483D1
Authority
DE
Germany
Prior art keywords
azahexan
heterocyclic
derivatives
antiviral effect
antiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69732483T
Other languages
English (en)
Other versions
DE69732483T2 (de
Inventor
Alexander Faessler
Guido Bold
Hans-Georg Capraro
Marc Lang
Chandra Khanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27171723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69732483(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE69732483D1 publication Critical patent/DE69732483D1/de
Application granted granted Critical
Publication of DE69732483T2 publication Critical patent/DE69732483T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02Compounds containing any of the groups, e.g. carbazates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02Compounds containing any of the groups, e.g. carbazates
    • C07C281/04Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69732483T 1996-04-22 1997-04-14 Heterocyclische Azahexanderivate mit antiviraler Wirkung Expired - Lifetime DE69732483T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CH101896 1996-04-22
CH101896 1996-04-22
CH2997 1997-01-08
CH2997 1997-01-08
CH22397 1997-01-31
CH22397 1997-01-31
PCT/EP1997/001860 WO1997040029A1 (en) 1996-04-22 1997-04-14 Antivirally active heterocyclic azahexane derivatives

Publications (2)

Publication Number Publication Date
DE69732483D1 true DE69732483D1 (de) 2005-03-17
DE69732483T2 DE69732483T2 (de) 2005-07-28

Family

ID=27171723

Family Applications (2)

Application Number Title Priority Date Filing Date
DE200512000003 Pending DE122005000003I1 (de) 1996-04-22 1997-04-14 Heterocyclische Azahexanderivate mit Antiviraler wirkung.
DE69732483T Expired - Lifetime DE69732483T2 (de) 1996-04-22 1997-04-14 Heterocyclische Azahexanderivate mit antiviraler Wirkung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE200512000003 Pending DE122005000003I1 (de) 1996-04-22 1997-04-14 Heterocyclische Azahexanderivate mit Antiviraler wirkung.

Country Status (28)

Country Link
EP (1) EP0900210B1 (de)
JP (1) JP3174347B2 (de)
CN (3) CN1082508C (de)
AR (1) AR006720A1 (de)
AT (1) ATE288903T1 (de)
AU (1) AU706183B2 (de)
BR (1) BR9701877A (de)
CA (3) CA2250840C (de)
CY (1) CY2596B2 (de)
CZ (1) CZ296135B6 (de)
DE (2) DE122005000003I1 (de)
DK (1) DK0900210T3 (de)
EA (1) EA001794B1 (de)
ES (1) ES2238720T3 (de)
FR (1) FR05C0030I2 (de)
HK (2) HK1018788A1 (de)
HU (1) HU224125B1 (de)
IL (1) IL126381A (de)
LU (1) LU91189I2 (de)
MY (1) MY114457A (de)
NL (1) NL300203I2 (de)
NO (2) NO313330B1 (de)
NZ (3) NZ332118A (de)
PT (1) PT900210E (de)
SI (1) SI0900210T1 (de)
SK (1) SK285048B6 (de)
TW (1) TW409125B (de)
WO (1) WO1997040029A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
EP1077977A1 (de) * 1998-05-15 2001-02-28 Abbott Laboratories Retrovirale protease inhibitoren
US6251906B1 (en) 1998-05-15 2001-06-26 Abbott Laboratories Retroviral protease inhibiting compounds
US6096894A (en) * 1998-07-29 2000-08-01 Sumika Fine Chemicals Co., Ltd. Production method of 2-(p-alkylphenyl)pyridine compound
DK0979820T3 (da) 1998-08-07 2003-06-02 Sumika Fine Chemicals Co Ltd 2-phenylpyridinderivater og fremgangsmåder til deres fremstilling
US6255349B1 (en) 1998-12-09 2001-07-03 American Home Products Corporation Alph-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
US6335350B1 (en) 1998-12-09 2002-01-01 American Home Products Corporation Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
US6197803B1 (en) 1998-12-09 2001-03-06 American Home Products Corporation Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
US6207715B1 (en) 1998-12-09 2001-03-27 American Home Products Corporation Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a substituted phenylene-diamine group
JP4222671B2 (ja) * 1999-02-15 2009-02-12 住友化学株式会社 ヒドラジン誘導体の製造方法
IT1313664B1 (it) * 1999-10-12 2002-09-09 Norpharma S P A Processo per la preparazione di un composto aril-piridinico.
US6365745B1 (en) 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
JP4278316B2 (ja) * 2000-07-14 2009-06-10 住友化学株式会社 ヒドラジン誘導体の製造方法
WO2004037790A1 (en) 2002-10-02 2004-05-06 Euticals Prime European Therapeuticals Spa Process for the preparation of aryl-piridyl compounds
US7943593B2 (en) * 2002-12-06 2011-05-17 Vertex Pharmaceuticals Incorporated Compositions comprising inhibitors of IMPDH enzyme
ITMI20032338A1 (it) * 2003-11-28 2005-05-29 Dinamite Dipharma S P A In Forma A Bbreviata Diph Composti feniltetrazolici.
CN1980666B (zh) * 2004-05-04 2011-03-30 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
EA013520B1 (ru) 2005-02-10 2010-06-30 Медивир Аб Ингибиторы протеазы вич
CA2657936C (en) * 2006-07-21 2017-01-10 Gilead Sciences, Inc. Antiviral protease inhibitors
PL2003120T3 (pl) 2007-06-12 2010-04-30 Concert Pharmaceuticals Inc Pochodne azapeptydu jako inhibitory proteazy HIV
WO2009130534A1 (en) * 2008-04-24 2009-10-29 Oxyrane (Pty) Ltd. Process for synthesizing atazanavir
EP2272830A1 (de) * 2009-06-18 2011-01-12 Esteve Química, S.A. Herstellungsverfahren für ein antivirales heterozyklisches Azahexan-Derivat
EP2272831A1 (de) 2009-06-26 2011-01-12 Prime European Therapeuticals S.p.A. Verfahren zur Herstellung von Arylpyridinylverbindungen
WO2011037467A1 (en) 2009-09-28 2011-03-31 Stichting Katholieke Universiteit Atazanavir for treating inflammatory diseases
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
US20130005780A1 (en) * 2010-03-01 2013-01-03 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
WO2012041488A1 (en) 2010-09-28 2012-04-05 Ratiopharm Gmbh Dry processing of atazanavir
WO2013014633A1 (en) * 2011-07-27 2013-01-31 Ranbaxy Laboratories Limited Process for preparation of atazanavir or its bisulfate salt
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN104163787A (zh) * 2014-08-08 2014-11-26 山东威智医药工业有限公司 阿扎那韦及其硫酸盐的制备方法
CN107459496B (zh) * 2016-06-03 2022-07-19 华东理工大学 噻唑类衍生物在治疗病毒感染中的应用
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CN107245052A (zh) * 2017-06-21 2017-10-13 连云港杰瑞药业有限公司 一种阿扎那韦制备方法
TWI829205B (zh) * 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN109574916A (zh) * 2018-12-29 2019-04-05 常州吉恩药业有限公司 阿扎那韦中间体2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的工业化生产方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN113603634B (zh) * 2021-08-06 2023-03-21 江苏八巨药业有限公司 一种阿扎那韦中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20010533A1 (en) * 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
DE59207226D1 (de) * 1991-07-03 1996-10-31 Ciba Geigy Ag Pharmakologisch wirksame Hydrazinderivate und Verfahren zu deren Herstellung
DE59303870D1 (de) * 1992-12-23 1996-10-24 Ciba Geigy Ag Antiretrovirale hydrazinderivate
DK1302468T3 (da) * 1992-12-29 2009-03-02 Abbott Lab Fremgangsmåder og mellemprodukter til fremstilling af forbindelser, der inhiberer retroviral protease
US5461067A (en) * 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
CA2250840A1 (en) 1997-10-30
AU706183B2 (en) 1999-06-10
PT900210E (pt) 2005-06-30
IL126381A0 (en) 1999-05-09
CY2596B2 (en) 2010-03-03
FR05C0030I1 (de) 2005-08-12
JP3174347B2 (ja) 2001-06-11
TW409125B (en) 2000-10-21
EA199800899A1 (ru) 1999-10-28
CA2510945A1 (en) 1997-10-30
DE122005000003I1 (de) 2005-05-25
CA2568104C (en) 2009-08-04
NO313330B1 (no) 2002-09-16
HK1018788A1 (en) 2000-01-07
NZ509046A (en) 2002-05-31
AR006720A1 (es) 1999-09-08
LU91189I2 (fr) 2005-10-03
CN1319587A (zh) 2001-10-31
CZ296135B6 (cs) 2006-01-11
ATE288903T1 (de) 2005-02-15
FR05C0030I2 (fr) 2007-04-27
CA2250840C (en) 2006-07-04
DE69732483T2 (de) 2005-07-28
ES2238720T3 (es) 2005-09-01
CN1216539A (zh) 1999-05-12
CA2510945C (en) 2007-01-16
EP0900210B1 (de) 2005-02-09
EA001794B1 (ru) 2001-08-27
NZ509045A (en) 2002-09-27
WO1997040029A1 (en) 1997-10-30
HUP9901612A3 (en) 2000-06-28
CN1193010C (zh) 2005-03-16
CN1082508C (zh) 2002-04-10
CZ337398A3 (cs) 1999-01-13
HK1075043A1 (en) 2005-12-02
CA2568104A1 (en) 1997-10-30
MY114457A (en) 2002-10-31
IL126381A (en) 2001-08-26
HUP9901612A2 (hu) 1999-08-30
DK0900210T3 (da) 2005-05-02
HU224125B1 (hu) 2005-05-30
SI0900210T1 (de) 2005-08-31
SK145298A3 (en) 1999-06-11
NZ332118A (en) 2001-02-23
JPH11511177A (ja) 1999-09-28
NO984900L (no) 1998-12-21
EP0900210A1 (de) 1999-03-10
NL300203I1 (nl) 2005-10-03
AU2385997A (en) 1997-11-12
SK285048B6 (sk) 2006-05-04
CN1616453A (zh) 2005-05-18
BR9701877A (pt) 1998-09-29
NO984900D0 (no) 1998-10-21
NO2005010I1 (no) 2005-05-02
LU91189I9 (de) 2018-12-27
NL300203I2 (nl) 2005-11-01
CN1310905C (zh) 2007-04-18

Similar Documents

Publication Publication Date Title
DE69732483D1 (de) Heterocyclische azahexan-derivate mit antiviraler wirkung
ATE234817T1 (de) Hetaroylcyclohexandionderivate mit herbizider wirkung
ATE264317T1 (de) Benzimidazol-derivate mit antihistaminischer wirkung
ATE323682T1 (de) Aryl-pyrimidin-derivate
DK0891332T3 (da) 6-phenylpyridyl-2-aminderivater
NO950879D0 (no) 3-fenylpyrrolidin-derivater
ATE421514T1 (de) 3-heteroxyclyl-substituierte benzoylderivate
NO981946D0 (no) Imidazoquinazolin-derivater
DE69831233D1 (de) Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
ATE255098T1 (de) Substituierte chromanderivate
DE69511086T2 (de) Pyrimidinderivate
ATE231508T1 (de) Azyklische nukleosidderivate
ATE255099T1 (de) Substituierte chromanderivate
NO954323D0 (no) Heterocykliske derivater
FI970110A0 (fi) Helico-bakteerin vastaisia heterosyklisiä atsolonijohdannaisia
DE69606165D1 (de) Bizyclische isothioharnstoff-derivate mit therapeutischer wirkung
DE69524611T2 (de) Pyrimidon-derivate
NO941135D0 (no) Tiazolpyrimidin derivater
IS5026A (is) 2-metoxýfenýlpíperasín afleiður
EE9800270A (et) Pürasool-4-üülhetaroüülderivaadid herbitsiididena
ATE225333T1 (de) Pyrrolderivate
FI972585A (fi) Virustenvastaisina aineina käyttökelpoiset tienoksatsinonijohdannaiset
DE59407726D1 (de) 3-Aryl-4-hydroxy-3-dihydrofuranon-Derivate
ATE214063T1 (de) Heterocyclische substituierte pyrrolidinamid- derivate
DE59508203D1 (de) Substituierte phthalimido-zimtsäurederivate mit herbizider wirkung

Legal Events

Date Code Title Description
R422 Decision on request for term extension (children's medicines) now final

Free format text: PRODUCT NAME: ATAZANAVIR UND/ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIERVON, INSBESONDERE ATAZANAV EU/1/03/267/001 BIS 007 20040302 IRSULFAT - REYATAZ ; NAT. REGISTRATION NO/DATE: EU/1/03/267/001-007 20040302; FIRST REGISTRATION: EU

Spc suppl protection certif: 122005000003

Filing date: 20050201

Expiry date: 20170415

Extension date: 20190904